PARP1 and ovarian serous carcinoma: To test the relative sensitivity of TNBC with silenced BRCA1 due to promoter hypermethylation (designated hereafter BRCA1-Me) to the PARP inhibitor olaparib and assess the impact of neoadjuvant treatment (NACT) on olaparib sensitivity, we selected 8 PDX models (7 TNBC and 1 High Grade Serous Ovarian Carcinoma) showing different BRCA1 profiles.